title: Transcatheter closure of perimembranous ventricular septal defects: initial human experience with the Amplatzer® membranous VSD occluder 2.
abstract: Although effective, transcatheter closure of perimembranous ventricular septal defects (pmVSD) with the Amplatzer Membranous VSD Occluder (AGA Medical Corporation, MN) carries a substantial risk of complete heart block, prompting many to abandon this intervention. A newly designed Amplatzer device for pmVSD was modified, in part, to minimize this risk. After rigorous preclinical testing, we report the first human experience with the Amplatzer Membranous VSD Occluder 2 (AGA Medical Corporation) in two patients (a 5-year old with a 12-mm pmVSD and a 26-year-old male with a 8-mm defect). Both procedures were successful, with no adverse events at 7 and 4 weeks of follow-up, respectively. Herein, we discuss characteristics of the new device, potential advantages compared to the prior version, and main technical aspects related to the procedure.
authors.affiliation: Service de Cardiologie Pédiatrique, Hôpital Sainte-Justine, Université de Montréal, Canada.
authors.forename: Daniel
authors.initials: D
authors.lastname: Velasco-Sanchez
authors.forename: Apostolos
authors.initials: A
authors.lastname: Tzikas
authors.forename: Reda
authors.initials: R
authors.lastname: Ibrahim
authors.forename: Joaquim
authors.initials: J
authors.lastname: Miró
mesh_terms: D000328:Adult; D006328:Cardiac Catheterization / Q000295:instrumentation*; D002675:Child, Preschool; D018618:Echocardiography, Doppler, Color; D005260:Female; D006345:Heart Septal Defects, Ventricular / Q000175:diagnosis / Q000628:therapy*; D006801:Humans; D008297:Male; D011474:Prosthesis Design; D055989:Septal Occluder Device; D016896:Treatment Outcome